Cipla has been assigned an Environmental, Social, and Governance (ESG) rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited. The rating was issued on September 11, 2026, and communicated directly to stock exchanges rather than the company.

The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also references SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Rating Communication Timeline

Niche, a SEBI-registered ESG Rating Provider, did not communicate the rating assignment to Cipla. Instead, the rating was sent directly to the National Stock Exchange of India Limited (NSE) on September 11, 2026, and to BSE Limited on September 17, 2026.

Cipla became aware of the rating through an alert disseminated by BSE at 5:50 pm on September 17, 2026. This followed BSE’s standard dissemination protocol.

Regulatory Context

The intimation serves as a mandatory disclosure under SEBI listing regulations. The company confirmed it received no prior communication from the rating agency regarding the assignment. The rating reflects the provider’s assessment based on publicly available information.

Rajendra Chopra, Company Secretary, signed the disclosure on September 18, 2026.

Cipla has received an Outperform rating from Macquarie with a target price of ₹1,675, as the brokerage assessed the compliance status of the company's Pithampur plant following its latest inspection.

Pithampur plant inspection: key findings

Macquarie noted that key observations from the Pithampur plant's previous inspection concerning Field Alert Report submission appear to have been addressed. However, the brokerage flagged that five repeat observations remain outstanding, indicating that the facility has not yet achieved full resolution of prior regulatory concerns.

The following table summarises the key compliance parameters highlighted by Macquarie:

Compliance concerns and remediation requirements

Macquarie identified microbial contamination and adverse environmental conditions as critical compliance concerns at the Pithampur plant. The brokerage indicated that robust remediation efforts and substantial Corrective and Preventive Action (CAPA) evidence will be required to satisfy the US Food and Drug Administration (FDA).

While the near-term earnings impact from the inspection findings is expected to be limited, the persistence of five repeat observations and the nature of the critical concerns underscore the importance of comprehensive remediation measures to meet regulatory standards.

Macquarie's rating and target

Macquarie maintained its Outperform rating on Cipla, setting a target price of ₹1,675. The assessment reflects the brokerage's view that progress has been made on certain prior observations, even as material compliance work remains at the Pithampur facility.